Tested medicine to treat liver scarring in PiZZ alpha-1 disease
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have alpha-1 antitrypsin PiZZ genetic type (PiZZ on records or confirmed by a special blood/genetic test).
- You’re 18 to 75 years old.
- Your liver biopsy shows scarring at METAVIR stage F2, F3, or F4 (from a biopsy during screening or a recent one within 6 months).
- Your lungs must meet the study’s breathing/lung requirements (and they will check for concerning lung issues).
- You must have no liver cancer (HCC) based on blood/ultrasound; extra CT/MRI may be needed if anything is unclear.
- You must not have serious “advanced liver” complications like swelling from fluid (ascites), certain bleeding, or severe confusion (encephalopathy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called fazirsiran, which is designed to treat alpha-1 antitrypsin deficiency-related liver disease with mild scarring. The goal is to see if fazirsiran is safe and can improve or slow liver damage in people with the PiZZ genetic type.
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
This trial tests a new drug called pegozafermin to see if it can help people with cirrhosis (scarring) of the liver caused by MASH (a fatty liver disease). If you have cirrhosis and either diabetes or multiple risk factors, this study might be an option for you.
This trial tests a new treatment called BEAM-302, which aims to correct the genetic defect that causes alpha-1 antitrypsin deficiency. It may help prevent further lung and liver damage in people with the PiZZ mutation.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests a new medicine called TSRA-196 for people with Alpha-1 Antitrypsin Deficiency who have the PiZZ genetic type. The study looks at whether TSRA-196 can help with lung or liver problems related to this condition.
Hear when a new Alpha1-Antitrypsin Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.